David W Meline Amgen Inc (AMGN) insider trading activity

David W Meline is EVP & CFO of AMGEN INC. Currently has a direct ownership of 49,378 shares of AMGN, which is worth approximately $13 Million. The most recent transaction as insider was on Nov 25, 2019, when has been sold 8,737 shares (Common Stock) at a price of $234.36 per share, resulting in proceeds of $2,047,603. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 49.4K

0% 3M change

0% 12M change

Total Value Held $13 Million

David W Meline Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 25 2019	SELL Open market or private sale	$2,047,603 $234.36 p/Share	8,737 Reduced 15.03%	49,378 Common Stock
May 03 2019	SELL Payment of exercise price or tax liability	$140,318 $176.5 p/Share	795 Reduced 1.47%	53,392 Common Stock
May 03 2019	BUY Grant, award, or other acquisition	-	4,511 Added 7.23%	57,903 Common Stock
May 01 2019	SELL Payment of exercise price or tax liability	$133,773 $179.32 p/Share	746 Reduced 1.36%	54,187 Common Stock
Mar 22 2019	SELL Payment of exercise price or tax liability	$1,542,796 $191.89 p/Share	8,040 Reduced 12.77%	54,933 Common Stock
Mar 06 2019	BUY Grant, award, or other acquisition	-	16,086 Added 20.41%	62,746 Common Stock
Jan 30 2019	SELL Payment of exercise price or tax liability	$101,434 $192.11 p/Share	528 Reduced 1.12%	46,660 Common Stock
Aug 01 2018	SELL Payment of exercise price or tax liability	$1,450,932 $196.55 p/Share	7,382 Reduced 12.39%	52,202 Common Stock
May 03 2018	SELL Payment of exercise price or tax liability	$130,969 $169.43 p/Share	773 Reduced 1.29%	59,382 Common Stock
Apr 27 2018	BUY Grant, award, or other acquisition	-	4,508 Added 6.97%	60,155 Common Stock
Mar 23 2018	SELL Payment of exercise price or tax liability	$1,329,228 $176.08 p/Share	7,549 Reduced 11.95%	55,647 Common Stock
Mar 07 2018	BUY Grant, award, or other acquisition	-	15,118 Added 19.37%	62,913 Common Stock
Jan 30 2018	SELL Payment of exercise price or tax liability	$98,208 $198.0 p/Share	496 Reduced 1.03%	47,795 Common Stock
Aug 01 2017	SELL Payment of exercise price or tax liability	$1,319,645 $174.51 p/Share	7,562 Reduced 13.63%	47,920 Common Stock
May 01 2017	BUY Grant, award, or other acquisition	-	4,305 Added 7.23%	55,227 Common Stock
Jan 30 2017	SELL Payment of exercise price or tax liability	$83,138 $157.16 p/Share	529 Reduced 1.03%	50,690 Common Stock
Aug 01 2016	SELL Payment of exercise price or tax liability	$1,163,955 $172.03 p/Share	6,766 Reduced 11.77%	50,741 Common Stock
May 03 2016	BUY Grant, award, or other acquisition	-	4,477 Added 7.26%	57,186 Common Stock
Aug 01 2015	SELL Payment of exercise price or tax liability	$1,270,742 $176.59 p/Share	7,196 Reduced 12.17%	51,934 Common Stock
Jan 30 2015	BUY Grant, award, or other acquisition	-	3,940 Added 6.31%	58,537 Common Stock
Aug 01 2014	BUY Grant, award, or other acquisition	-	54,161 Added 50.0%	54,161 Common Stock

Also insider at

MRNA

Moderna, Inc. Healthcare

Chief Financial Officer

PACB

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Healthcare

Director

HPQ

HP INC Technology

DWM

David W Meline

EVP & CFO

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMGN shares.

Notify only if

Value

Insider Trading

Get notified when an Amgen Inc insider buys or sells AMGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to AMGEN INC

Track Activities on AMGN

Account